Chinese pharmaceuticals company Clover Biopharmaceuticals announced that their new potential Covid-19 vaccine, dubbed SCB-2019, was proven 79% effective against the Delta variant.
In a large trial conducted by Clover, 207 symptomatic Covid-19 cases were reported at least two weeks after the second dose, 52 of which were from a vaccinated group, while the remaining 155 were from a control placebo group, Reuters reports.
The vaccine also showed an 83.7% efficacy against moderate-to-severe infections and 100% against hospitalization caused by Covid-19.
Over 30,000 adults in Brazil, Colombia, the Philippines, South Africa and Belgium participated in the trial, receiving two doses of the vaccine at a 21-day interval.
“We are pleased that SCB-2019 has successfully demonstrated efficacy against the globally dominant Delta strain and other concerning variants,” Clover CEO Joshua Liang said in a statement.
The company said it would submit its trial data for conditional approval to the World Health Organization and regulators in China and Europe in the fourth quarter of 2021.
Clover is set to provide 414 million doses of the SCB-2019 vaccine through the global vaccine sharing initiative COVAX.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.